ArticleCureus2026
Priapism After Initiation of Long-Acting Injectable Risperidone: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Priapism is an uncommon but serious urological emergency, defined as a persistent penile erection unrelated to sexual stimulation. If not promptly treated, it carries a significant risk of permanent erectile dysfunction. Among pharmacologically induced causes, antipsychotic medications are frequently implicated. We describe the case of an 18-year-old male diagnosed with cannabis-induced psychosis who developed acute ischemic priapism within 24 hours of receiving his first dose of long-acting injectable risperidone. The patient required urgent urological management, which resulted in complete resolution of the episode. Risperidone was subsequently discontinued, and treatment was switched to olanzapine, gradually titrated to 10 mg/day. This change was associated with full remission of psychotic symptoms, without recurrence of priapism. This case underscores the importance of early recognition of priapism, careful antipsychotic selection, and patient counseling, particularly when initiating long-acting injectable formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.